Company profile: Pathios Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule GPR65 inhibitors to develop therapies for autoimmune diseases and cancer, targeting the pH-sensing GPCR GPR65 to counteract immunosuppressive polarization of immune cells. Offerings include PTT-4256, an orally bioavailable, highly potent and selective GPR65 inhibitor for cancer, and CNS-optimized GPR65 inhibitors for malignant brain tumors.
Products and services
- GPR65 Inhibitors for Brain Tumors: CNS-optimized small molecule antagonists target pH-sensing GPR65 to treat malignant brain tumors by reversing immunosuppressive effects within the acidic tumor microenvironment
- PTT-4256: Orally-bioavailable, highly potent and selective GPR65 inhibitor counters immunosuppressive effects in the acidic tumor microenvironment to treat cancer
- Small Molecule GPR65 Inhibitors for Autoimmune Diseases and Cancer: Custom-engineered compounds target pH-sensing GPR65 to counteract immunosuppressive polarization of immune cells, advancing therapies for autoimmune disorders and oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pathios Therapeutics
Apitope
HQ: United Kingdom
Website
- Description: Provider of discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis; first product candidate licensed to Merck Serono.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apitope company profile →
SetPoint Medical
HQ: United States
Website
- Description: Provider of neuroimmune modulation solutions for chronic autoimmune conditions, including a platform that activates immunomodulatory pathways via targeted electrical stimulation to regulate inflammation, and a small vagus nerve stimulation device with integrated circuit, telemetry and rechargeable battery controlled via iPad. Also conducts clinical research, including RESET-RA, a randomized, double-blind rheumatoid arthritis study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SetPoint Medical company profile →
Flame Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage therapies for cancer and other inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flame Biosciences company profile →
MiroBio
HQ: United Kingdom
Website
- Description: Provider of an antibody platform based on University of Oxford research into immune cell communication and activation, creating antibodies that leverage natural signalling mechanisms to restore immune system balance and control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MiroBio company profile →
Endpoint Health
HQ: United States
Website
- Description: Provider of precision immunology solutions, including targeted therapeutics tailored to patient biology for immune-mediated diseases, companion diagnostics to personalize treatment, a precision immunology ecosystem with pharma, biotech, diagnostics providers and clinical data registries, and clinical collaborations with over 60 global health systems to develop precision therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endpoint Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pathios Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pathios Therapeutics
2.2 - Growth funds investing in similar companies to Pathios Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pathios Therapeutics
4.2 - Public trading comparable groups for Pathios Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →